Context dependent benzodiazepine modulation of GABA(A) receptor opening frequency.
The anxiolytic, hypnotic, and anti-convulsant properties of benzodiazepines (BDZs) require modulation of distinct GABA(A) receptor alpha-subtypes. BDZ modulation of GABA(A) receptors is often described in terms of increased opening frequency, and contrasted with the increased open durations occurring with barbiturate modulation. Several studies spanning single channel, rapid kinetic, and whole cell techniques have suggested that BDZs effect this observed change in frequency through increased affinity for GABA. BDZ-sensitive αβγ isoforms exist at extrasynaptic as well as synaptic locations, where they encounter markedly different concentration and time-course of GABA exposure. Interestingly, this affinity-based mechanism (specifically, decreasing the GABA unbinding rate) is only predicted to increase opening frequency under conditions that allow the unbinding and rebinding cycles typical of prolonged exposure to low GABA concentrations, which are more likely to occur at extrasynaptic GABA(A) receptors. In contrast, when rebinding is less likely, such as may occur in certain synaptic conditions, the number, but not the frequency, of channel openings increases in response to BDZ modulation. In conclusion, not only can multiple kinetic mechanisms alter channel opening frequency, but a single mechanism - increased affinity - impacts opening frequency differently under different contexts of GABA(A) receptor activation.
Bianchi
Matt T
MT
Neurology Department, Sleep Division, Massachusetts General Hospital, Wang 720, Boston, MA, 02114, USA. mtbianchi@partners.org
J Neurosci. 1998 Nov 1;18(21):8590-604
9786967
Br J Pharmacol. 1998 Nov;125(5):924-47
9846630
Trends Neurosci. 1996 Apr;19(4):139-43
8658597
Trends Neurosci. 1996 Mar;19(3):96-101
9054063
J Neurosci. 2001 Dec 1;21(23):9083-91
11717341
Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3674-9
14990800
Eur J Neurosci. 2000 Mar;12(3):810-8
10762310
Neuron. 2007 Dec 6;56(5):763-70
18054854
Nature. 1999 Oct 21;401(6755):796-800
10548105
J Neurosci. 2004 Jul 28;24(30):6785-90
15282283
J Physiol. 1989 Oct;417:483-500
2482885
Nat Rev Neurosci. 2005 Mar;6(3):215-29
15738957
J Neurophysiol. 2003 Feb;89(2):871-83
12574465
J Neurosci. 1999 Jan 15;19(2):578-88
9880578
Proc Natl Acad Sci U S A. 2001 May 22;98(11):6464-9
11353839
Anesthesiology. 2005 Apr;102(4):783-92
15791108
Mol Pharmacol. 2007 Feb;71(2):483-93
17108261
Neuropharmacology. 1996;35(9-10):1383-92
9014155
Trends Neurosci. 2004 May;27(5):262-9
15111008
J Neurosci. 2002 Jul 1;22(13):5321-7
12097483
Prog Biophys Mol Biol. 2005 Jan;87(1):33-46
15471589
Nature. 1977 Sep 22;269(5626):342-4
561893
Nature. 1978 Feb 9;271(5645):563-4
563985
J Neurophysiol. 2002 May;87(5):2624-8
11976398
Neuroreport. 1999 Mar 17;10(4):817-21
10208554
Mol Pharmacol. 2000 Nov;58(5):1129-36
11040062
Br J Pharmacol. 1999 Jul;127(6):1349-58
10455284
Science. 2000 Oct 6;290(5489):131-4
11021797
Eur J Neurosci. 2006 May;23(9):2495-504
16706856
Results Probl Cell Differ. 2008;44:29-48
17671772
J Physiol. 2007 Nov 1;584(Pt 3):769-87
17884921
Epilepsy Res. 2009 Aug;85(2-3):212-20
19447010
J Neurosci. 2005 Aug 31;25(35):8056-65
16135763
Br J Pharmacol. 2000 Apr;129(8):1794-800
10780988
Br J Pharmacol. 2000 Dec;131(7):1251-4
11090095
J Physiol. 1999 Jan 1;514 ( Pt 1):27-45
9831714
Ann Neurol. 1989 Mar;25(3):213-20
2471436
Neuron. 1995 Jul;15(1):181-91
7542462
J Physiol. 2007 Feb 1;578(Pt 3):655-76
17124266
Eur J Neurosci. 2003 May;17(10):2226-30
12786990
Sleep Med Rev. 2005 Dec;9(6):477-87
16233983
Neuropharmacology. 1996;35(9-10):1169-79
9014132
Neuropharmacology. 2001 Nov;41(6):737-44
11640928
Biophys J. 2001 Mar;80(3):1251-61
11222289
J Physiol. 2007 Nov 15;585(Pt 1):29-46
17855751
J Physiol. 2001 Dec 15;537(Pt 3):715-33
11744750
Trends Neurosci. 2004 Sep;27(9):569-75
15331240
Br J Pharmacol. 2005 Aug;145(7):894-906
15912137
Neuroreport. 2007 May 28;18(8):781-5
17471066
Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217
10209232
Pharmacol Ther. 2006 Dec;112(3):612-29
16876255
J Physiol. 1994 Feb 15;475(1):69-82
7514665
Neuropharmacology. 2009 Jan;56(1):161-73
18775733
Mol Pharmacol. 1999 Jan;55(1):168-78
9882711
J Neurosci. 2000 Nov 1;20(21):7914-21
11050111
Br J Pharmacol. 2006 Aug;148(7):984-90
16783415